Dumonteil E, McMahon-Pratt D, Price VL

Idioma: Ingles.
Referencias bibliográficas: 8
Paginas: 53-58
Archivo PDF: 31.82 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. 1.- Sharifi I, FeKri A R, Aflatonian M R, Khamesipour A,Nadim A, Ahmadi-Mousavi M R, et al Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniases in Bam, Iran. Lancet 1998; 351: 1540-3.

2. Modabber F. First generation leishmaniases vaccines in clinical development: Moving, but what next? Curr Opin Anti-infect Invest Drugs 2000; 2: 35-9.

3. 3.- Velez I D, del Pilar Agudelo S, Arbelaez M P, Gilchrist K, Robledo S M, Puerta J A, et al. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans R Soc Trop Med Hyg 2000; 94: 698-703.

4. 4.- da Silva VO, Borja-Cabrera G P, Correia Pontes N N, de Souza E P, Luz K G, Palatnik M, et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 2000; 19: 1082-92.

5. 5.- Stager S, Smith D F, Kaye PM. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 2000; 165: 7064-71.

6. 6.- Gicheru M M, Olobo J O, Anjili C O, Orago A S,Modabber F, Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and IL-12 develop a type 1 response, but are not protected against challenge infection. Infect Immun 2001; 69: 245-51.

7. 7.- Park A Y, Hondowicz B D, Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol 2000; 165: 896-902.

8. 8.- Aebischer T, Wolfram M, Patzer S I, Ilg T, Wiese M, Overath P. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect Immun 2000; 68:1328-36.